INOZYME PHARMA, INC.
321 Summer Street, Suite 400
Boston, MA 02210
November 13, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tyler Howes
| Re: | Inozyme Pharma, Inc. |
Registration Statement on Form S-3
File No. 333-275364
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Inozyme Pharma, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-275364), so that it may become effective at 4:30 p.m. Eastern time on November 15, 2023, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
| Very truly yours, | ||
| INOZYME PHARMA, INC. | ||
| By: | /s/ Sanjay Subramanian | |
| Name: | Sanjay Subramanian | |
| Title: | Chief Financial Officer | |
| cc: | Caroline Dotolo, Esq. |
Wilmer Cutler Pickering Hale and Dorr LLP